Nuclear Medicine, Molecular imaging, Oncology, Urinary Tract / Bladder, PET-CT, SPECT-CT, PET, Radionuclide therapy, Treatment effects, Safety, Radiotherapy techniques, Metastases, Quality assurance, Not applicable
M. Vyas; Auckland/NZ
Prostate cancer is one of the significant threat to men’s health all over the world and the second leading cause of death in the United States of America. 25,000 NZ men are currently living with a diagnosis of prostate cancer (MOH,2018) 3000 new cases are being diagnosed with prostate cancer, each year and 560 are likely to die each year from metastatic prostate cancer.
Currently, much attention is being given to the development of precision medicine in oncology. Earlier Radioisotope-labelled choline was used to determine the stage of prostate cancer (Schwenck et al., 2017). In the last few years, lots of studies indicated that radioisotope labelled Prostate-specific membrane antigen (PSMA) is an active agent for the diagnosis as well as for the treatment of metastatic prostate cancer condition (Bouchelouche, Choyke, & Capala, 2010).